<DOC>
	<DOCNO>NCT00005083</DOCNO>
	<brief_summary>RATIONALE : New image procedure , functional magnetic resonance image 1H-nuclear magnetic resonance spectroscopic imaging , may improve ability detect extent cancer brain . PURPOSE : Phase II trial study effectiveness functional magnetic resonance image 1H-nuclear magnetic resonance spectroscopic image treat patient newly diagnose brain tumor .</brief_summary>
	<brief_title>Functional Magnetic Resonance Imaging 1H-Nuclear Magnetic Resonance Spectroscopic Imaging Treating Patients With Newly Diagnosed Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine definable topospecific relationship functional neuroactivation measure functional magnetic resonance imaging ( fMRI ) chemostructural tissue measurement make 1H-nuclear magnetic resonance spectroscopic imaging ( 1H-NMRSI ) patient newly diagnose brain tumor situate vicinity brain 's language motor region . II . Determine clinical improvement correlate stronger image signature neuroactivation fMRI patient population . III . Determine functional loss tumor recurrence progression correlate increase choline decrease N-acetylaspartate 1H-NMRSI region previously display activation fMRI associate underlying white matter region patient . OUTLINE : Patients undergo preoperative functional magnetic resonance imaging ( fMRI ) , 1H-nuclear magnetic resonance spectroscopic imaging ( 1H-NMRSI ) , conventional contrast MRI 2 hour follow neurofunctional motor and/or language neurofunctional testing . Intraoperatively , patient undergo corticography consist awake language map motor cortex stimulation . Patients undergo repeat image neurofunctional evaluation 2 week follow surgery prior radiotherapy chemotherapy . Patients also undergo neurological neuropsychological test consist basic gait , motor coordination , reflex , hand motor , tongue motor , language evaluation measure baseline , preoperative , postoperative clinical status outcome . Patients follow every 4 month 1 year . PROJECTED ACCRUAL : A total 40 patient accrue study 4 year .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose brain tumor Neuroradiological clinical evidence probable glioma Lesion close proximity language motor area No prior resection PATIENT CHARACTERISTICS : Age : 18 55 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No medical psychiatric disorder No contraindication MRI scanning ( e.g. , metal implant , dental prosthesis filling , contrast allergy ) PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>